Sheng-Jie Liu1,2,3, Jiang-Yi Wang1,2,3, Shuang-He Peng1,2,3, Teng Li1,2,3, Xiang-Hui Ning1,2,3, Bao-An Hong1,2,3, Jia-Yuan Liu1,2,3, Peng-Jie Wu4, Bo-Wen Zhou1,2,3, Jing-Cheng Zhou1,2,3, Nie-Nie Qi1,2,3, Xiang Peng1,2,3, Jiu-Feng Zhang1,2,3, Kai-Fang Ma1,2,3, Lin Cai5,6,7, Kan Gong5,6,7. 1. Department of Urology, Peking University First Hospital, Beijing, P.R. China. 2. Institute of Urology, Peking University, Beijing, P.R. China. 3. National Urological Cancer Center, Beijing, P.R. China. 4. Department of Urology, Beijing Hospital, Beijing, P.R. China. 5. Department of Urology, Peking University First Hospital, Beijing, P.R. China. drcailin@163.com. 6. Institute of Urology, Peking University, Beijing, P.R. China. drcailin@163.com. 7. National Urological Cancer Center, Beijing, P.R. China. drcailin@163.com.
Abstract
PURPOSE: Von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that reduces life expectancy. We aimed to construct a more valuable genotype-phenotype correlation based on alterations in VHL protein (pVHL). METHODS: VHL patients (n = 339) were recruited and grouped based on mutation types: HIF-α binding site missense (HM) mutations, non-HIF-α binding site missense (nHM) mutations, and truncating (TR) mutations. Age-related risks of VHL-associated tumors and patient survival were compared. RESULTS: Missense mutations conferred an increased risk of pheochromocytoma (HR = 1.854, p = 0.047) compared with truncating mutations. The risk of pheochromocytoma was lower in the HM group than in the nHM group (HR = 0.298, p = 0.003) but was similar between HM and TR groups (HR = 0.901, p = 0.810). Patients in the nHM group had a higher risk of pheochromocytoma (HR = 3.447, p < 0.001) and lower risks of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than those in the combined HM and TR (HMTR) group. Moreover, nHM mutations were independently associated with better overall survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations. CONCLUSION: The modified genotype-phenotype correlation links VHL gene mutation, substrate binding site, and phenotypic diversity (penetrance and survival), and provides more accurate information for genetic counseling and pathogenesis studies.
PURPOSE: Von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome that reduces life expectancy. We aimed to construct a more valuable genotype-phenotype correlation based on alterations in VHL protein (pVHL). METHODS: VHL patients (n = 339) were recruited and grouped based on mutation types: HIF-α binding site missense (HM) mutations, non-HIF-α binding site missense (nHM) mutations, and truncating (TR) mutations. Age-related risks of VHL-associated tumors and patient survival were compared. RESULTS: Missense mutations conferred an increased risk of pheochromocytoma (HR = 1.854, p = 0.047) compared with truncating mutations. The risk of pheochromocytoma was lower in the HM group than in the nHM group (HR = 0.298, p = 0.003) but was similar between HM and TR groups (HR = 0.901, p = 0.810). Patients in the nHM group had a higher risk of pheochromocytoma (HR = 3.447, p < 0.001) and lower risks of central nervous system hemangioblastoma (CHB) (HR = 0.700, p = 0.045), renal cell carcinoma (HR = 0.610, p = 0.024), and pancreatic tumor (HR = 0.382, p < 0.001) than those in the combined HM and TR (HMTR) group. Moreover, nHM mutations were independently associated with better overall survival (HR = 0.345, p = 0.005) and CHB-specific survival (HR = 0.129, p = 0.005) than HMTR mutations. CONCLUSION: The modified genotype-phenotype correlation links VHL gene mutation, substrate binding site, and phenotypic diversity (penetrance and survival), and provides more accurate information for genetic counseling and pathogenesis studies.
Entities:
Keywords:
genotype–phenotype; protein binding site; survival; tumor risk; von Hippel–Lindau disease
Authors: Morgan Nordstrom-O'Brien; Rob B van der Luijt; Ellen van Rooijen; Ans M van den Ouweland; Danielle F Majoor-Krakauer; Martijn P Lolkema; Aram van Brussel; Emile E Voest; Rachel H Giles Journal: Hum Mutat Date: 2010-05 Impact factor: 4.878
Authors: Shuanghe Peng; Matthew J Shepard; Jiangyi Wang; Teng Li; Xianghui Ning; Lin Cai; Zhengping Zhuang; Kan Gong Journal: Oncotarget Date: 2017-06-13
Authors: Andreea Chiorean; Kirsten M Farncombe; Sean Delong; Veronica Andric; Safa Ansar; Clarissa Chan; Kaitlin Clark; Arpad M Danos; Yizhuo Gao; Rachel H Giles; Anna Goldenberg; Payal Jani; Kilannin Krysiak; Lynzey Kujan; Samantha Macpherson; Eamonn R Maher; Liam G McCoy; Yasser Salama; Jason Saliba; Lana Sheta; Malachi Griffith; Obi L Griffith; Lauren Erdman; Arun Ramani; Raymond H Kim Journal: Hum Mutat Date: 2022-05-10 Impact factor: 4.700
Authors: Francisco R Fields; Niraja Suresh; Morgan Hiller; Stefan D Freed; Kasturi Haldar; Shaun W Lee Journal: PLoS One Date: 2020-11-05 Impact factor: 3.240